Stages Archives - Page 3 of 19

In Silico Drug Discovery Platform

WuXi AppTec offers a comprehensive platform of in silico drug discovery services to accelerate the process of hit finding and...

Creating a Biological Switch Using DEL Technology

In addition to identifying chemical starting points for early drug discovery processes, DNA-encoded library (DEL) technology has now expanded to...

Integrated Screening in Hit Identification

Despite the availability of modern screening technologies, identification and optimization of hits against poorly druggable targets remains a significant challenge...

Heme Oxygenase-1-Targeting Molecules

WuXi AppTec scientists published a study in the open access archive ChemRxiv describing the discovery of highly selective, novel, heme...

PROTAC Optimization Strategies

What if a constructed PROTAC with a confirmed high-affinity warhead doesn’t work as expected? That means we need to take...

Addition of Covalent Warhead and DEL-Generated Hit Fragmentation Empower FBDD

Fragment-based drug discovery (FBDD) is one of the most well-developed approaches for projects starting from small, low-affinity compounds. At the...

DEL Insight: Novel Applications with the Bifunctional Linker of DNA-encoded Molecules

Due to the special configuration of the DNA encoded library (DEL), each DEL molecule carries a DNA sequence encoding its...

Covalent Fragment-based Drug Discovery: BTK Inhibitors

At the Covalent Drug Discovery 2023 Summit and Fragments 2024 Conference, we presented a case study on Bruton’s tyrosine kinase (BTK)...

One Stop Target-to-Hit Platform: CDKs and CDK-Cyclin Complexes

Cyclin-dependent kinases (CDKs) and their cyclin regulatory subunits form complexes that are essential for driving abnormal growth processes in cancer...

Knowledge Library